leisure time -WSS

leisure time

author：entertainment 2025-10-02 20:47:28 - browse：5

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Group behind ProMed defends move to subscription

WSS

The best solution to the drug shortages problem

H.R. 3 is the wrong path to lower drug costs

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

South Korea throws huge K

Pharma showers House GOP doctor with campaign cash

Pharma showers House GOP doctor with campaign cash

explore

leisure time

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

CDC recommends RSV monoclonal antibody for infants

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Medical records are filled with copy

Drastic changes should bring profitability, startup health insurers say

New air purifier tech could be key to improving indoor air quality

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Wildfire smoke exposes gaps in outdoor worker protections

The a glaring gap in research on serious mental illness and primary care

focus

2 officers injured in shooting in Orlando, police say

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

NIH trials fail to test meaningful long Covid therapies, experts say

Personalized medicine goes far beyond genetics

Personalized medicine goes far beyond genetics

Anavex keeps shifting the goalposts in its clinical trials

focus

explore

entertainment

explore